Ayunova Pharmaceutical LLP

Mabura Injection contains Adalimumab 40 mg, a recombinant human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-α). It is used in the treatment of various autoimmune and inflammatory disorders by reducing inflammation and controlling disease progression. Mabura Adalimumab Injection Pen is designed for convenient subcutaneous administration and should be used strictly under medical supervision.

• Active Ingredient:
  Adalimumab – 40 mg

• Dosage Form:
  Prefilled injection pen

• Route of Administration:
  Subcutaneous

• Excipients:
  q.s.

Mabura Adalimumab Injection is indicated for:

• Rheumatoid arthritis

• Ankylosing spondylitis

• Psoriatic arthritis

• Plaque psoriasis

• Crohn’s disease and ulcerative colitis

• Other autoimmune disorders as prescribed by a physician

(Prescription medicine – hospital and specialty use only)

• Administered via subcutaneous injection

• Dosage and frequency as prescribed by the treating physician

• Patient training recommended for self-administration

• Do not shake the pen before use

• Store at 2°C – 8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Kyfil Injection contains Carfilzomib 60 mg, a selective proteasome inhibitor used for the treatment of multiple myeloma. Carfilzomib irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome, leading to apoptosis of malignant plasma cells and slowing disease progression. Kyfil is intended for intravenous use and should be administered only under the supervision of trained oncology healthcare professionals.

• Active Ingredient:
  Carfilzomib – 60 mg per vial

• Excipients:
  q.s.

• Dosage Form:
  Lyophilized powder for injection

Kyfil Carfilzomib Injection is indicated for:

• Relapsed or refractory multiple myeloma

• As part of combination therapy with other antineoplastic agents, as prescribed by the oncologist

(Prescription medicine – oncology and hospital use only)

• Administered via intravenous infusion after reconstitution

• Dosage depends on patient condition, body surface area, and combination regimen

• To be administered only by trained healthcare professionals

• Monitor for infusion-related reactions, cardiac, renal, and hepatic functions during therapy

• Store at 2°C – 8°C (refrigerated)

• Protect from light

• Do not freeze

• Keep out of reach of children

Enoxaparin Injection is a low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat blood clots. Each 0.4 ml prefilled syringe contains 40 mg of Enoxaparin Sodium, which works by inhibiting clotting factors, primarily factor Xa, reducing the risk of thromboembolic events. This injection is intended for subcutaneous administration under medical supervision.

• Active Ingredient:
  Enoxaparin Sodium – 40 mg per 0.4 ml

• Excipients:
  q.s.

• Dosage Form:
  Prefilled syringe for subcutaneous injection

• Pharmacopoeial Standard:
  IP / USP

Enoxaparin 40 mg Injection is indicated for:

• Prevention of deep vein thrombosis (DVT) in patients undergoing surgery

• Treatment and prevention of venous thromboembolism (VTE)

• Management of acute coronary syndromes (ACS) such as unstable angina and non-ST-elevation myocardial infarction (NSTEMI)

• Other conditions requiring anticoagulation therapy as prescribed by a physician

(Prescription medicine – hospital and clinical use only)

• Administered via subcutaneous injection as directed by the physician

• Prefilled syringe ready for use; do not shake

• Injection site should be rotated to reduce local reactions

• Monitor patient for signs of bleeding or hematologic changes

• Store 2°C – 8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

METHORA Tablets contain Methotrexate 5 mg, an antimetabolite and immunosuppressant used in the treatment of autoimmune disorders and certain cancers. Methotrexate inhibits dihydrofolate reductase, reducing abnormal cell growth and immune activity. METHORA Tablets must be used strictly under the supervision of a qualified physician due to the risk of serious adverse effects if misused.

• Active Ingredient:
  Methotrexate IP – 5 mg per tablet

• Excipients:
  q.s.

• Dosage Form:
  Tablet

• Pharmacopoeial Standard:
  IP

METHORA Methotrexate Tablets are indicated for:

• Rheumatoid arthritis and other autoimmune disorders

• Psoriasis (moderate to severe)

• Certain malignancies such as leukemia and lymphomas

• Other conditions as prescribed by a physician

(Prescription medicine – use under strict medical supervision)

• Take orally only as prescribed by the physician

• Usually administered once weekly for non-oncological indications

• Tablets should be swallowed whole with water

• Regular monitoring of blood counts, liver, and kidney function is essential

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children